TCM
IBER

Tegean Capital Management’s Ibere Pharmaceuticals IBER Stock Holding History

Tegean Capital Management’s Portfolio IBER Stock Details IBER Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-45,711
Closed -$448K – 54
2022
Q2 		$448K Hold
45,711
– – 0.02% 40
2022
Q1 		$448K Hold
45,711
– – 0.47% 43
2021
Q4 		$444K Buy
+45,711
New +$444K 0.45% 49

Other funds holding IBER

GCL
Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return
MF
Magnetar Financial Evanston, Illinois $9.84B AUM 190.64% 1-Year Est. Return
Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return
PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.27% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
FTCM
First Trust Capital Management Chicago, Illinois $1.9B AUM 58.39% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
PC
Periscope Capital Toronto, Ontario, Canada $902M AUM 6.51% 1-Year Est. Return
KL
KIM LLC Wichita, Kansas $976M AUM 0.91% 1-Year Est. Return
LA
Linden Advisors New York $17.9B AUM 1.72% 1-Year Est. Return

Tegean Capital Management's IBER Position: Q3 2022 in Review

Tegean Capital Management sold out of Ibere Pharmaceuticals (IBER) in Q3 2022, closing a stake of 45,711 shares — an estimated $448K sold.

Tegean Capital Management first reported a position in IBER in Q4 2021 and held it in 3 quarters. The position peaked at $448K in Q2 2022. 48 funds tracked by Wall St. Rank hold IBER as of Q3 2022.

  • Tegean Capital Management reported no remaining Ibere Pharmaceuticals position as of Q3 2022 after selling out during the quarter.
  • Tegean Capital Management sold 45,711 Ibere Pharmaceuticals shares in Q3 2022, an estimated $448K.
  • Tegean Capital Management first reported a position in Ibere Pharmaceuticals in Q4 2021 and held it in 3 quarters.
  • Tegean Capital Management's Ibere Pharmaceuticals position peaked at $448K in Q2 2022.
  • 48 funds tracked by Wall St. Rank held Ibere Pharmaceuticals as of Q3 2022.

Based on Tegean Capital Management's 13F filing for Q3 2022, filed 14 Nov 2022.